Annual Meeting Offers Industry Education and Entertainment
|
By LabMedica International staff writers Posted on 08 Jun 2017 |

Image: Genome editing with CRISPR-Cas9 offers the potential to treat human genetic disease (Photo courtesy of Feng Zhang).
Registration has opened for the 2017 annual meeting of the American Association of Clinical Chemistry, which has promised novel and interesting sessions that will highlight emerging science, practices, and technologies across the spectrum of clinical laboratory medicine.
The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.
The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.
The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.
A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.
Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley
The 69th AACC Annual Scientific Meeting & Clinical Lab Expo will be held in San Diego, CA, USA, from July 30 to August 3. In addition to a strong lineup of plenary speakers, which will be headed by Dr. Jennifer Doudna, professor of chemistry and molecular and cell biology at the University of California, Berkeley (USA) – who will be speaking about advances in CRISPR/Cas9 gene editing technology – there will be a mock courtroom session and two quiz games.
The mock trial session will illustrate the importance of expert witness testimony in resolving litigation associated with toxicology and clinical laboratories. One quiz game will pit the AACC leadership against members of the Society for Young Clinical Laboratorians. The teams will contest various laboratory medicine topics such as oncology and cardiovascular biomarkers, molecular testing, point-of-care testing, therapeutic drug management/toxicology, and over-utilized or outdated tests.
The second quiz game will engage the audience on topics addressing Zika virus, mass spectrometry, antimicrobial resistance, and other infectious disease issues and diagnostic solutions.
A highlight of the conference will be the Qualcomm Tricorder XPRIZE special session. Two participants in this $10 million global competition to develop devices capable of diagnosing at least 13 health conditions and continuously monitoring five vital signs, all with a consumer-friendly interface and weighing no more than five pounds (2.27 kilograms), will present their innovations.
Related Links:
AACC Annual Scientific Meeting & Clinical Lab Expo
University of California, Berkeley
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more








